Bayer(US:BAYRY) Zheng Quan Ri Bao·2025-11-07 15:34Core Insights - Bayer's Eylea® 8mg (Aflibercept 8mg) was launched during the China International Import Expo, approved for treating neovascular age-related macular degeneration (nAMD) in May 2023, offering a more effective and longer-interval treatment option for patients [1][2] Group 1: Product Overview - Eylea® 8mg provides a treatment regimen starting with monthly injections for the first three months, which can then be extended to every four months based on clinical assessment [1] - The product aims to enhance treatment adherence and quality of life for nAMD patients, addressing unmet medical needs [1][2] Group 2: Clinical Validation - The clinical value of Eylea® 8mg was validated in the pivotal Phase III PULSAR study, showing comparable vision improvement with longer injection intervals compared to the 2mg dosage [2] - Eylea® 8mg demonstrated a faster and higher rate of fluid resolution during the loading phase, addressing the need for reduced injection frequency while maintaining vision benefits [2] Group 3: Market Context - nAMD is a progressive eye disease leading to irreversible vision loss, with the number of affected individuals in China projected to rise from 4.5 million in 2020 to 8.8 million by 2050 [1] - Without timely intervention, approximately 75.7% of nAMD patients may progress to legal blindness within three years, highlighting the urgent need for effective treatment solutions [1]